Monoclonal antibodies (mAbs) are now one of the leading classes of biotherapeutics, with total sales expected to surpass hundreds of billions of US dollars in the next year. They also comprise over fifty percent of first-time regulatory approvals. To further enhance the therapeutic properties and efficacy of mAbs, researchers are focusing on developing more optimized methods and engineering processes through cell line selection and genetic modifications.

In this whitepaper explore the potential of next-generation genome editing tools for helping drive the success of monoclonal antibodies as biotherapeutics. Along with the considerations to take when designing more potent therapeutic antibodies.

Areas covered include:

• Choosing the right cell line
• Why post-translational modifications matter
• Afucosylation benefits
• Altering glycan composition through gene editing

For research use only. Not for use in diagnostic procedures.